SU-11739 (other developmental code names AGN-1133, J-508; also known as N-methyl-N-propargyl-1-aminoindane) is an experimental monoamine oxidase inhibitor...
7 KB (534 words) - 07:05, 1 October 2024
it metabolizes into (R)-1-aminoindan (TVP-136) and has no such actions. SU-11739 (AGN-1133; N-methyl-N-propargyl-1-aminoindan), the N-methylated analogue...
90 KB (8,896 words) - 00:46, 20 October 2024
is slightly more potent than D-deprenyl. AGN-1135 (racemic rasagiline) SU-11739 (racemic N-methylated rasagiline) Parnham, M. J. (1993). "The History of...
7 KB (517 words) - 21:14, 17 October 2024
concomitant catecholaminergic activity enhancer (CAE) actions, like rasagiline, SU-11739, and lazabemide, are poorly effective in reversing behavioral deficits...
93 KB (10,159 words) - 03:18, 20 October 2024
desmethylselegiline, rasagiline and its racemic N-methylated analogue SU-11739 (AGN-1133, J-508) are devoid of CAE actions. In fact, rasagiline actually...
137 KB (13,992 words) - 23:53, 18 October 2024
C13H15N (molar mass: 185.27 g/mol) may refer to: Naphthylaminopropane SU-11739 This set index page lists chemical structure articles associated with the...
500 bytes (51 words) - 13:33, 22 September 2024
and its metabolite (R)-1-aminoindan do not have MAE actions. Similarly, SU-11739 (AGN-1133; J-508), the N-methylated analogue of rasagiline and a closer...
54 KB (5,655 words) - 00:16, 20 October 2024
pharmaceutical drug rather than AGP-1135. Deprenyl (the racemic form of selegiline) SU-11739 (the racemic N-methyl analogue of rasagiline) Desmethylselegiline (DMS;...
4 KB (212 words) - 02:30, 15 September 2024
– selective irreversible MAO-B inhibitor and neuroprotective agent SU-11739 (AGN-1133; J-508; N-methyl-N-propargyl-1-aminoindane) – non-selective monoamine...
10 KB (739 words) - 05:54, 14 September 2024
(in Persian). Ministry of the Interior, Board of Ministers. Proposal 53.1.11739; Notification 17168/T909. Archived from the original on 20 April 2012. Retrieved...
6 KB (383 words) - 00:05, 15 October 2024